452 unknown. 452 Phase 1, 210 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 452 | Unknown 452 |
| Phase 2 | 210 | Unknown 210 |
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma UTAA09 injection - Recurrent or Refractory B-cell Non Hodgkin's Lymphoma | Phase 1 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 10 | 2024-07-31 | 2024-07-16 |
| L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma L218CAR19 - Relapsed/Refractory B-cell Lymphomas | Phase 1 | Unknown | Henan Cancer Hospital | 22 | 2024-06-01 | 2024-06-27 |
| Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma Anti-BCMA CAR-NK - Multiple Myeloma, Refractory | Phase 1 / Phase 2 | Unknown | Shahid Beheshti University of Medical Sciences | 10 | 2024-04-30 | 2024-03-06 |
| F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma After preconditioning with chemotherapy, F01 will be evaluated. - Non-Hodgkin's Lymphoma | Phase 1 | Unknown | Shanghai Simnova Biotechnology Co.,Ltd. | 55 | 2024-04-01 | 2024-02-23 |
| A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma CM313 injection - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Keymed Biosciences Co.Ltd | 120 | 2024-02-28 | 2023-11-13 |
| INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia INS19 CAR-T Cells - Leukemia, B-cell | Phase 1 | Unknown | Beijing Immunochina Medical Science & Technology Co., Ltd. | 12 | 2024-01-15 | 2024-01-17 |
| CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors CD19&CD20 bispecific CAR-T cells - B-Cell Lymphoblastic Leukemia/Lymphoma | Phase 1 / Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 80 | 2024-01-14 | 2024-07-16 |
| A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma KQ-2003 CAR T-cells - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | 29 | 2024-01-11 | 2024-01-25 |
| A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma SHR2554/CHOP, SHR2554/CHOEP - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 100 | 2023-12-22 | 2024-05-14 |
| Safety and Efficacy Evaluation of Next-generation CD19-UCART CD19-UCART - Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma | Phase 1 | Unknown | Bioray Laboratories | 20 | 2023-12-20 | 2023-01-27 |
| Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL mitoxantrone liposome 16 and azacitidine, mitoxantrone liposome 18 and azacitidine, mitoxantrone liposome 20 and azacitidine - Angioimmunoblastic T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huijing Wu | 30 | 2023-12-12 | 2024-01-25 |
| Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma BEBT-908 for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Unknown | BeBetter Med Inc | 75 | 2023-12-01 | 2023-12-11 |
| A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma SHR-A1912; R-Chemo - B-cell Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | Shanghai Hengrui Pharmaceutical Co., Ltd. | 132 | 2023-11-17 | 2023-12-27 |
| Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab Blinatumomab - Acute Lymphoblastic Leukemia | Phase 1 | Unknown | Zhejiang University | 31 | 2023-11-16 | 2023-11-09 |
| A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 42 | 2023-10-30 | 2023-11-02 |
| A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . TQB3909 tablet - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 107 | 2023-10-11 | 2023-10-23 |
| QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia QH103 Cell Injection, Fludarabine, Cyclophosphamide - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Unknown | Anhui Provincial Hospital | 10 | 2023-09-27 | 2023-10-24 |
| Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study Linperlisib in combined with Chidamide - Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 32 | 2023-09-25 | 2023-10-16 |
| A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) GFH009 - Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Phase 1 / Phase 2 | Unknown | Genfleet Therapeutics (Shanghai) Inc. | 95 | 2023-09-06 | 2024-12-13 |
| FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis FKC288 - Light Chain Amyloidosis | Phase 1 | Unknown | Nanjing University School of Medicine | 12 | 2023-08-29 | 2023-11-15 |
Showing 20 of 452. Sign in to see all of them.
Multiple Myeloma (114) · Lymphoma (100) · Lymphoma, B-Cell (69) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (69) · Lymphoma, Non-Hodgkin (65) · Recurrence (60) · Leukemia, Lymphocytic, Chronic, B-Cell (45) · Burkitt Lymphoma (43) · Lymphoma, Large B-Cell, Diffuse (41) · Leukemia (35) · Lymphoma, Follicular (30) · Lymphoma, Mantle-Cell (29) · Hodgkin Disease (27) · Leukemia, B-Cell (22) · Leukemia, Myeloid, Acute (21)
Immune System Diseases (450) · Immunoproliferative Disorders (450) · Hemic and Lymphatic Diseases (449) · Neoplasms by Histologic Type (446) · Neoplasms (437) · Lymphatic Diseases (351) · Hematologic Diseases (261) · Lymphoma (195) · Lymphoma, Non-Hodgkin (153) · Leukemia, Lymphoid (126) · Leukemia (121) · Paraproteinemias (121) · Cardiovascular Diseases (120) · Hemorrhagic Disorders (120)
Cyclophosphamide (52) · fludarabine (36) · Dexamethasone (20) · Rituximab (18) · Immunotherapy, Adoptive (12) · Lenalidomide (12) · Etoposide (10) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (10) · Bortezomib (9) · Prednisone (9) · Vincristine (9) · fludarabine phosphate (8) · Antigens, CD19 (7) · Bendamustine Hydrochloride (7) · Melphalan (7)
Chinese PLA General Hospital (18) · Chongqing Precision Biotech Co., Ltd (9) · Henan Cancer Hospital (9) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (8) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (7) · Second Affiliated Hospital, Zhejiang University, School of Medicine (7) · Zhejiang University (7) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (6) · Peking Union Medical College Hospital (6) · Peking University (6) · Southwest Hospital, China (6) · Beijing Immunochina Medical Science & Technology Co., Ltd. (5) · Hebei Senlang Biotechnology Inc., Ltd. (5) · Shenzhen Second People's Hospital (5) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (4)
China (277) · United States (77) · South Korea (11) · United Kingdom (11) · Australia (8) · Canada (7) · Germany (7) · Spain (7) · Italy (6) · Poland (5) · Russia (5) · Singapore (5) · France (4) · Israel (4) · Denmark (3)
Cheng Qian, PhD (6) · Cheng Qian, MD, PhD (5) · Sanbin Wang, MD (5) · Heng Mei, M.D., Ph.D (4) · Jun Zhu, MD (4) · Yifan Zhai, MD, PhD (4) · Jie Jin, MD (3) · Suzin Mayerson, PhD (3) · Wenbin Qian (3) · Wenbin Qian, MD, PhD (3) · Yongping Song (3) · Gang An (2) · Gerald L. DeNardo, MD (2) · He Huang, Doctor (2) · He Huang, MD (2)
PMID 34515338, PMID 36100310, PMID 36536403, PMID 37192741, PMID 40195173, PMID 28054442, PMID 35126471, PMID 35799791, PMID 37658205, PMID 42826832, PMID 10632319, PMID 15016963, PMID 15112270, PMID 16564913, PMID 16818691, PMID 18077538, PMID 18596230, PMID 18616528, PMID 18794884, PMID 20371346, PMID 20626398, PMID 20959411, PMID 21911830, PMID 22589701, PMID 24311149, PMID 24382970, PMID 24450857, PMID 24450858, PMID 24497570, PMID 24523121, PMID 24615776, PMID 24615777, PMID 24641416, PMID 24963497, PMID 25444722, PMID 25621950, PMID 25631767, PMID 25682597, PMID 25805929, PMID 25983002, PMID 26687796, PMID 26819050, PMID 27053773, PMID 27347147, PMID 27442600, PMID 27579615, PMID 27843120, PMID 27916294, PMID 28039295, PMID 28129122
2019 (2), P30CA060553 (2), 2014 (1), 2015 (1), 2016 (1), 2017 (1), P30CA015083 (1), P30CA016672 (1), P30CA138292 (1)